Alphanox to Acquire Additional Shares of U.S. Subsidiary for 5.6 Billion KRW
Alphanox announced on the 19th that it will acquire an additional 4 million shares of its U.S. implant sales subsidiary (Solco Biomedical) for approximately 5.6 billion KRW.
After the acquisition, Alphanox's ownership stake will become 100%. The scheduled date of share acquisition is the 23rd.
Hot Picks Today
"Oops, No Condom... 'I Probably Won't Get Pregnant' – Alarming Neglect of Contraception Among Korean Adolescents"
- Now Is Not the Time to Sell Samsung Electronics and SK hynix...Securities Firms Say "The Market Greatly Misunderstood"[Weekend Money]
- Four-Vehicle Collision and Car Fire at Daegwallyeong 4 Tunnel on Yeongdong Expressway
- Thought It Was Clean, but It's Dirtier Than a Toilet... Rinsing Only With Water Leaves 40,000 Bacteria
- "No Need for Private Academies: Saving 800,000 Won a Month and Boosting Grades... Parents Flock After Hearing the News"
The company stated that the purpose of this acquisition is to strengthen business competitiveness in the U.S. market and to improve its financial structure.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
